Glenmark Pharmaceuticals receives final approval for Clobetasol Propionate Topical Solution

From USFDA

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Topical Solution USP, 0.05%, the generic version of Temovate1 Topical Solution, 0.05%, of Fougera Pharmaceuticals, Inc. This product will be manufactured at Glenmark's Baddi plant in India.

According to IQVIATM sales data for the 12 month period ending February 2018, the Temovate Topical Solution, 0.05% market2 achieved annual sales of approximately $46.2 million*.

Powered by Capital Market - Live News